| 0 (0%) | 01-14 09:33 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 17.82 |
1-year : | 20.81 |
| Resists | First : | 15.26 |
Second : | 17.82 |
| Pivot price | 13.91 |
|||
| Supports | First : | 13.9 |
Second : | 13.06 |
| MAs | MA(5) : | 14.8 |
MA(20) : | 13.76 |
| MA(100) : | 15 |
MA(250) : | 15.1 |
|
| MACD | MACD : | 0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 88.9 |
D(3) : | 87.8 |
| RSI | RSI(14): 65.4 |
|||
| 52-week | High : | 19.5 | Low : | 11.5 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ HCM ] has closed below upper band by 10.4%. Bollinger Bands are 36.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 15.28 - 15.34 | 15.34 - 15.38 |
| Low: | 14.68 - 14.75 | 14.75 - 14.81 |
| Close: | 14.84 - 14.95 | 14.95 - 15.04 |
Wed, 14 Jan 2026
Unmasking a Genetic Driver of Dilated Cardiomyopathy in People of African Ancestry - Cleveland Clinic
Tue, 13 Jan 2026
Mavacamten Shows Improvements for Pediatric Obstructive Hypertrophic Cardiomyopathy - Drug Topics
Tue, 13 Jan 2026
BMS reports positive results in Phase III SCOUT-HCM trial for oHCM - Clinical Trials Arena
Mon, 12 Jan 2026
Charter School Finds Better Fit HCM Provider - CBIZ
Mon, 12 Jan 2026
SDOH Shape HCM Risk and Outcomes on Equity in Cardiac Care: Neha Hafeez, MD - AJMC
Mon, 12 Jan 2026
Obstructive vs. Nonobstructive HCM: What’s the Difference? - Everyday Health
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 172 (M) |
| Held by Insiders | 5.0902e+008 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 369 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 2.65 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 633.29 |
| Profit Margin | 77.5 % |
| Operating Margin | -1.3 % |
| Return on Assets (ttm) | -0.9 % |
| Return on Equity (ttm) | 46.9 % |
| Qtrly Rev. Growth | -9.2 % |
| Gross Profit (p.s.) | 1.05412e+008 |
| Sales Per Share | 1.18078e+009 |
| EBITDA (p.s.) | -1.46863e+007 |
| Qtrly Earnings Growth | 1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -33 (M) |
| PE Ratio | 5.64 |
| PEG Ratio | 0 |
| Price to Book value | 0.02 |
| Price to Sales | 0 |
| Price to Cash Flow | 5.33 |
| Dividend | 0 |
| Forward Dividend | 393760 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|